France Liquid Biopsy Market Size & Outlook, 2025-2033
- Clinical Diagnostics
- In Vitro Diagnostics
- Liquid Biopsy Market Outlook
- In Vitro Diagnostics
Global Market
Related Markets
Ask Prism AI about the liquid biopsy market
Get cited answers from GVR research on market growth, segments, regulations and forecasts.
- Source-linked answers
- Market-specific context
- Traceable figures
France liquid biopsy market highlights
- The France liquid biopsy market generated a revenue of USD 358.6 million in 2025 and is expected to reach USD 875.7 million by 2033.
- The France market is expected to grow at a CAGR of 11.8% from 2026 to 2033.
- In terms of segment, blood sample based was the largest revenue generating sample type in 2025.
- Blood Sample Based is the most lucrative sample type segment registering the fastest growth during the forecast period.
Liquid biopsy market data book summary
| Market revenue in 2025 | USD 358.6 million |
| Market revenue in 2033 | USD 875.7 million |
| Growth rate | 11.8% (CAGR from 2026 to 2033) |
| Largest segment | Blood sample based |
| Fastest growing segment | Blood Sample Based |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Blood Sample Based |
| Key market players worldwide | ANGLE PLC, Guardant Health Inc, Myriad Genetics Inc, Biocept Inc, Lucence Health, Roche, Qiagen NV, Illumina Inc, Thermo Fisher Scientific Inc, Epigenomics AG, Oncimmune, Freenome |
Other key industry trends
- In terms of revenue, France accounted for 2.6% of the global liquid biopsy market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Europe, Germany liquid biopsy market is projected to lead the regional market in terms of revenue in 2033.
- UK is the fastest growing regional market in Europe and is projected to reach USD 2,366.8 million by 2033.
The growth of France market can primarily be attributed to extensive government initiatives that are boosting the adoption of liquid biopsy solutions in the country. Since 2013, the French National Cancer Institute (INCa) has supported the implementation of targeted NGS as part of routine clinical practice.
Moreover, in September 2023, Roche France, in partnership with the Institute Gustave Roussy and Foundation Medicine, Inc., announced the establishment of in-house liquid biopsy testing in France with the utilization of Foundation Medicine’s FoundationOne Liquid CDx to provide genomic testing to cancer patients in the country.
The growing cancer prevalence and increasing burden of chronic diseases on the healthcare industry are further anticipated to drive market growth. In October 2022, the My Personal Breast Cancer Screening (MyPeBS) clinical trial was conducted in Belgium, which aimed to evaluate a breast cancer screening plan based on individual risk.
No credit card required*
Publish Date: Jun 16, 2026
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
- Turnaround
- 5–10 working days
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Liquid Biopsy Market Scope
Liquid Biopsy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Illumina Inc | View profile | 9,300 | 5200 Illumina Way, San Diego, CA, United States, 92122 | www.illumina.com |
| Qiagen NV | View profile | 5,900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | www.qiagen.com |
| ANGLE PLC | View profile | 165 | 10 Nugent Road, The Surrey Research Park, Surrey, Guildford, United Kingdom, GU2 7AF | www.angleplc.com |
| Myriad Genetics Inc | View profile | 2,700 | 320 Wakara Way, Salt Lake City, UT, United States, 84108 | www.myriad.com |
| Biocept Inc | View profile | 50 | 9955 Mesa Rim Road, San Diego, CA, United States, 92121 | www.biocept.com |
| Guardant Health Inc | View profile | 1,779 | 3100 Hanover Street, Palo Alto, CA, United States, 94304 | www.guardanthealth.com |
| Epigenomics AG | View profile | 18 | Geneststrasse 5, Berlin, BB, Germany, 10829 | www.epigenomics.com |
| Roche | View profile | 10001+ | Basel, Basel-Stadt, Switzerland, Europe | www.roche.com |
| Lucence Health | View profile | 51-100 | Palo Alto, California, United States, North America | www.lucence.com/ |
France Liquid Biopsy Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Liquid Biopsy Market Outlook will help companies and investors design strategic landscapes.
Blood Sample Based was the largest segment with a revenue share of 81.15% in 2025.
Horizon Databook has segmented the France liquid biopsy market based on blood sample based covering the revenue growth of each sub-segment from 2021 to 2033.
The growth of France market can primarily be attributed to extensive government initiatives that are boosting the adoption of liquid biopsy solutions in the country. Since 2013, the French National Cancer Institute (INCa) has supported the implementation of targeted NGS as part of routine clinical practice.
Moreover, in September 2023, Roche France, in partnership with the Institute Gustave Roussy and Foundation Medicine, Inc., announced the establishment of in-house liquid biopsy testing in France with the utilization of Foundation Medicine’s FoundationOne Liquid CDx to provide genomic testing to cancer patients in the country.
The growing cancer prevalence and increasing burden of chronic diseases on the healthcare industry are further anticipated to drive market growth. In October 2022, the My Personal Breast Cancer Screening (MyPeBS) clinical trial was conducted in Belgium, which aimed to evaluate a breast cancer screening plan based on individual risk.
- France Liquid Biopsy Market Sample Type Outlook (Revenue, USD Million , 2021-2033)
- Blood Sample Based
- Others
- France Liquid Biopsy Market Biomarker Outlook (Revenue, USD Million , 2021-2033)
- Circulating Nucleic Acids
- CTC
- Exosomes/Microvesicles
- Circulating Proteins
- France Liquid Biopsy Market Technology Outlook (Revenue, USD Million , 2021-2033)
- Multi-gene-parallel Analysis (NGS)
- Single Gene Analysis (PCR Microarrays)
- France Liquid Biopsy Market Application Outlook (Revenue, USD Million , 2021-2033)
- Cancer
- Reproductive Health
- Others
- France Liquid Biopsy Market End Use Outlook (Revenue, USD Million , 2021-2033)
- Hospitals and Laboratories
- Specialty Clinics
- Academic and Research Centers
- Others
- France Liquid Biopsy Market Clinical Application Outlook (Revenue, USD Million , 2021-2033)
- Therapy Selection
- Treatment Monitoring
- Early Cancer Screening
- Recurrence Monitoring
- Others
- France Liquid Biopsy Market Product Outlook (Revenue, USD Million , 2021-2033)
- Instruments
- Consumables Kits and Reagents
- Software and Services
Reasons to subscribe to Liquid Biopsy Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Liquid Biopsy Market Outlook databook
- Our clientele includes a mix of Liquid Biopsy Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the France Liquid Biopsy Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into France Liquid Biopsy Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
France Liquid Biopsy Market, 2021-2033 (US$M)
France Sample Type - Liquid Biopsy Market Statistics, 2024 - 2033 (US$M)
